Ipamorelin side effects and safety considerations

Ipamorelin's short-term tolerability looks unremarkable, and its selectivity means the cortisol and prolactin effects associated with older GHRPs are not expected. But "unremarkable" here rests on very little data: one randomized trial in 114 post-surgical patients, one healthy-volunteer pharmacology study, and two adverse-event reports in FDA's national database. In the trial, three findings were more frequent on ipamorelin than placebo — hyperglycemia at discharge (14.3% vs 8.6%), hypokalemia (12.5% vs 3.4%), and insomnia (10.7% vs 5.2%) (FDA briefing document, 2024).

The phase 2 postoperative ileus study randomized 114 adults recovering from bowel resection to intravenous ipamorelin 0.03 mg/kg twice daily or placebo. The authors reported that most adverse events were mild to moderate and related to surgery or underlying disease, with overall rates similar between groups (87.5% on ipamorelin, 94.8% on placebo) (Beck et al., Int J Colorectal Dis 2014).

• Nausea, vomiting, and abdominal distention were the most common events in both arms, numerically lower on ipamorelin.
• Hyperglycemia at discharge, hypokalemia, and insomnia were each more frequent on ipamorelin.
• Three ipamorelin patients stopped the drug for nausea, hypertension, or hypotension; three placebo patients stopped for hyponatremia, vomiting, nausea, or distention.
• Serious adverse events occurred in 17.9% of ipamorelin patients and 15.5% of placebo patients, mostly infection, anastomotic leak, and readmission. Two deaths occurred in the ipamorelin arm, both in colon-cancer patients with postoperative complications.

Two points of interpretation. This population — people who have just had a section of bowel removed — is nothing like the healthy adults who buy the compound, so the event rates transfer poorly in either direction. And a trial of 114 people cannot establish or rule out a causal link for events this uncommon; the honest reading is that the study was too small to resolve them.

Most of what can be said about longer-term risk comes from the class rather than from ipamorelin itself. A review of growth hormone secretagogues found them generally well tolerated but singled out increases in blood glucose driven by decreased insulin sensitivity, and called explicitly for evaluation of cancer incidence and mortality with long-term use (Sigalos & Pastuszak, Sex Med Rev 2018).

The most informative long-term dataset in the class is the two-year MK-677 trial in 65 healthy older adults: fasting glucose rose about 5 mg/dL, insulin sensitivity fell, and the most frequent complaints were increased appetite, transient mild lower-extremity edema, and muscle pain (Nass et al., Ann Intern Med 2008). Fluid retention and joint aches track GH elevation generally, so they are plausible with any effective secretagogue — including ipamorelin, whose selectivity concerns other pituitary hormones, not GH's own downstream effects.

FDA's 2024 evaluation is unusually direct about the gaps, and they are worth listing plainly:

• Carcinogenicity: no publicly available non-clinical study informs ipamorelin's carcinogenic potential.

• Reproductive safety: because it acts as a ghrelin-receptor agonist, reviewers judged it "may also negatively affect reproductive health and pregnancy outcomes," extrapolating from ghrelin-pathway work in mice.

• Reinforcement: the same mechanism means it "may have behavioral reinforcing properties, which can contribute to development of addiction."

• Toxicology overall: the available non-clinical studies were "too limited in scope and duration" to inform any clinical use.

Post-marketing signals are equally sparse — not reassuring, just absent. A search of the FDA Adverse Event Reporting System through September 2023 returned two non-serious reports involving compounded ipamorelin: tearing and headache after a nasal spray, and elbow joint pain after two months of an ipamorelin/sermorelin injection. A related database covering supplements returned none.

A distinct category of risk has nothing to do with pharmacology. FDA's chemists concluded ipamorelin is "not well characterized" as a bulk substance: there is no USP monograph, and the certificates of analysis circulating from suppliers typically report purity only — no impurity profile, no aggregate data, no bacterial endotoxin testing. Those are precisely the attributes that determine immunogenicity risk in an injected peptide.

Separately, analysis of seized black-market "growth promoting" products found Gly-ipamorelin — ipamorelin with an extra N-terminal glycine — rather than ipamorelin itself (Krug et al., Growth Horm IGF Res 2018). Whatever the safety profile of ipamorelin turns out to be, it does not apply to a molecule that isn't ipamorelin.

For what the compound is supposed to do, see ipamorelin benefits; for how it is administered, see dosing education.